Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer: Comparison of thyroid-stimulating hormone stimulation methods

Nuclear Medicine Communications

Volumn 32, Issue 9, 2011, Pages 840-846

  Vallejo Casas, Juan Antonio ^a   Mena Bares, Luisa M ^a   Gálvez, María Ángeles ^a   Marlowe, Robert J ^b   Latre Romero, José M ^a   Martínez Paredes, María ^c  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Spencer Fontayne Corporation   (United States)

^c UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

differentiated thyroid cancer; dose rate; Iodine 131; pharmacoeconomics; radioiodine; radioiodine thyroid remnant ablation; recombinant human thyroid stimulating hormone; thyroid hormone withdrawal; treatment room length of stay; treatment room patient throughput

Indexed keywords

LEVOTHYROXINE; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROTROPIN;

ABLATION THERAPY; ADULT; ARTICLE; CANCER HORMONE THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; RADIATION DOSE; RETROSPECTIVE STUDY; SCINTIGRAPHY; SPAIN; STIMULATION; THYROID HORMONE WITHDRAWAL; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TISSUE DISTRIBUTION;

ABLATION TECHNIQUES; ADULT; FEMALE; HUMANS; IODINE RADIOISOTOPES; LENGTH OF STAY; MALE; PATIENTS' ROOMS; RADIATION DOSAGE; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROTROPIN; TIME FACTORS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 80051785630     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32834863b0     Document Type: Article

References (21)

1. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-3885. (Pubitemid 30644169)
2. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91:926-932. (Pubitemid 43357760)
3. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306. (Pubitemid 28065257)
4. Taieb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol (Oxf) 2009;71:115-123.
5. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 2010;20:173-179.
6. Borget I, Schlumberger M, Allyn M, De Pouvoirville G, Remy H, Ricard M. Radioiodine ablation in thyroid cancer patients: comparison of length and cost of hospital stay between preparation by thyroid hormone withdrawal and Thyrogen. Eur J Endocrinol 2008;35:1457-1463.
7. Remy H, Borget I, Leboulleux S, Guilabert N, Lavielle F, Garsi J, et al. 131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med 2008;49:1445-1450.
8. Taieb D, Sebag F, Farman-Ara B, Portal T, Baumstarck-Barrau K, Fortanier C, et al. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. J Clin Endocrinol Metab 2010;95:3283-3290.
9. Park S-G, Reynolds JC, Brucker-Davis F, Whatley M, McEllin K, Maxted D, et al. Iodine kinetics during I-131 scanning in patients with thyroid cancer: comparison of studies with recombinant human TSH (rhTSH) versus hypothyroidism. J Nucl Med 1996;37:15P, abstr 49
10. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006;47:648-654. (Pubitemid 46768466)
11. Vaiano A, Claudio Traino A, Boni G, Grosso M, Lazzeri P, Colato C, et al. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal. Nucl Med Commun 2007;28:215-223. (Pubitemid 46192957)
12. Berg G, Lindstedt G, Suurkula M, Jansson S. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 2002;25:44-52. (Pubitemid 34168339)
13. Mernagh P, Campbell S, Dietlein M, Luster M, Mazzaferri E, Weston AR. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 2006;155:405-414. (Pubitemid 44463946)
14. Stajduhar KI, Neithercut J, Chu E, Pham P, Rohde J, Sicotte A, et al. Thyroid cancer: patients' experiences of receiving iodine-131 therapy. Oncol Nurs Forum 2000;27:1213-1218.
15. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, et al. Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nucl Med Commun 2006;27:627-632. (Pubitemid 44305303)
16. Rosario PW, Borges MA, Purisch S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med 2008;49:1776-1782.
17. Chianelli M, Todino V, Graziano FM, Panunzi C, Pace D, Guglielmi R, et al. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol 2009;160:431-436.
18. Robbins RJ, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 2002;43:1482-1488. (Pubitemid 35285874)
19. Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008;49:764-770. (Pubitemid 351717542)
20. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, et al. Ablation of thyroid residues with 30 mCi (131) I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002;87:4063-4068.
21. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poggiu A, et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007;92:3542-3546. (Pubitemid 47435333)